Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.51 |
| ▸ | RORC | P51449 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
| ▸ | KLK1 | P06870 | 1/20 | 0.47 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PARG | Q86W56 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6258857 | 0.92 | MMP13 (0.51) | RXFP1MAPTMMP13SLC22A8SMN1; SMN2 | |
| SCHEMBL7014327 | 0.90 | MAPT (0.58) | RXFP1MAPTMMP13SMN1; SMN2PPARG | |
| SCHEMBL6246256 | 0.88 | MAPT (0.58) | RXFP1MAPTMMP13SLC22A8SMN1; SMN2 | |
| SCHEMBL6234634 | 0.88 | MMP13 (0.58) | RXFP1MAPTMMP13SMN1; SMN2PPARG | |
| SCHEMBL6437738 | 0.87 | RXFP1 (0.53) | RXFP1MAPTMMP13SMN1; SMN2PPARG | |
| SCHEMBL6254595 | 0.87 | POLB (0.54) | RXFP1MAPTMMP13SMN1; SMN2PPARG | |
| SCHEMBL7625585 | 0.87 | MMP13 (0.53) | RXFP1MAPTMMP13SLC22A8SMN1; SMN2 | |
| SCHEMBL6260402 | 0.85 | KLKB1 (0.55) | RXFP1MAPTMMP13KLKB1SMN1; SMN2 | |
| SCHEMBL7097679 | 0.85 | MMP13 (0.60) | RORCMAPTMMP13SLC22A8SMN1; SMN2 | |
| SCHEMBL6259580 | 0.84 | MMP13 (0.61) | RXFP1MAPTMMP13SLC22A8PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368324-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-12-10 | — | — | EP | claimed |
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | ANDRIANJARA CHARLES (FR) | 2002-12-19 | — | — | US | claimed |
| WO-2002064572-A1 | QUINAZOLINES AS MMP-13 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193377-A1 | Quinazolines as MMP-13 inhibitors | MMP13, MMP9, MMP3 | RXFP1 83/4885RORC 1297/4885ADORA2A 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.